(TGTX) TG Therapeutics, Inc. Business Model Canvas Research

Jubilant Biosys gives TG Therapeutics external discovery and development firepower, helping move preclinical and early-stage programs without building a large in-house team. In a lean biotech model, this kind of outsourced scientific capacity helps control fixed costs and keep capital focused on late-stage assets and commercialization.

• Supports preclinical work
• Extends early-stage R&D capacity
• Keeps TG Therapeutics lean

TG Therapeutics’ alliances with LFB, GTC, Ildong, and Rhizen extend its reach across 4 partners, helping it tap regional expertise for development, licensing, and commercialization. This network spreads program risk and can speed access in Europe and Asia while TG keeps a multi-partner option set.

• 4 strategic partners
• Broader geographic reach
• Development and licensing optionality
• Regional commercialization support

TG Therapeutics, Inc. must run regulatory filings, CMC (chemistry, manufacturing, and controls), and launch execution in lockstep, because BRIUMVI is now a commercial product, not just a clinical asset. In 2025, that meant keeping FDA and supply-chain work aligned with market access, so every approval step could turn into paid prescriptions.

• Regulatory filings keep market access open.
• CMC coordination protects supply and quality.
• Launch execution converts trials into sales.

TG Therapeutics, Inc. licenses and manages three preclinical programs in BET, IRAK4, and GITR, so it can keep future shots on goal without overcommitting cash today. This supports pipeline renewal and gives the Company optionality as it turns BRIUMVI revenue into longer-term growth.

• 3 preclinical programs: BET, IRAK4, GITR
• Preserves future pipeline options
• Supports long-term renewal

TG Therapeutics, Inc. uses a partnership and licensing network to widen its scientific reach, tap external know-how, and access molecules and regional paths it may not build alone. That spreads risk away from one internal discovery engine and can speed development and deal flow.

• Broader science access
• Lower single-engine risk
• Regional market reach

TG Therapeutics, Inc.'s biotech expertise, regulatory execution, and commercial launch know-how are core resources behind BRIUMVI's U.S. growth. Its patent and licensed IP estate helps protect differentiation, support pricing power, and sustain long-term market value.

• Scientific and regulatory know-how
• Patent and licensed-program protection
• Supports BRIUMVI differentiation

TG Therapeutics, Inc. uses oral small-molecule oncology programs, including TG-1701 and the legacy umbralisib platform, to hit PI3K-delta, CK1-epsilon, and BTK pathways. Oral dosing can cut clinic burden and widen use versus infusions; TG Therapeutics, Inc. reported $0.0M from umbralisib after its 2022 withdrawal, so pipeline fit matters more than legacy sales.

• Oral route improves convenience.
• Multi-pathway targeting may boost efficacy.
• BTK and PI3K-delta are validated cancer targets.
• Current value depends on TG-1701 success.

TG Therapeutics, Inc. uses a multi-modality immuno-oncology pipeline: cosibelimab adds a checkpoint mechanism, and TG-1801 adds a bispecific approach. That gives the Company two distinct ways to hit cancer biology, so it is less tied to one pathway and can spread clinical risk across programs.

• Checkpoint plus bispecific coverage
• Two shots at harder-to-treat tumors
• Less dependence on one mechanism

TG Therapeutics, Inc. uses patient access and reimbursement support to help commercial specialty-drug users clear payer checks, prior auth, and copay hurdles. That matters for BRIUMVI adoption and retention, since access friction can delay starts and push patients off therapy.

• Helps patients start therapy faster
• Supports reimbursement and payer steps
• Improves persistence on treatment

Safety monitoring and follow-up are part of TG Therapeutics, Inc. customer relationships because specialty biologics need ongoing pharmacovigilance after the first prescription. In its latest reporting, TG Therapeutics, Inc. said BRIUMVI net product revenue reached $314.4 million in 2024, so post-launch safety tracking helps protect trust with neurologists, regulators, and payers.

• Track adverse events after dosing
• Support clinician confidence and adherence
• Strengthen regulator-facing safety data

TG Therapeutics, Inc. uses medical congresses and peer-reviewed publications to share Phase 3 evidence from ULTIMATE I and II, helping physicians and payers judge BRIUMVI on data, not promotion. This evidence-led channel builds trust fast, especially in a market where one approved MS product can still face payer scrutiny and step-edits.

• Shares trial data at congresses
• Supports peer-reviewed credibility
• Helps win physician trust
• Helps support payer access

TG Therapeutics, Inc. can use digital HCP and patient support to reinforce education, speed onboarding, and keep patients on therapy between visits. That matters as BRIUMVI net product sales reached $389.5 million in 2025, so stronger digital support can help protect access and adherence while face-to-face promotion stays the main driver.

• Supports onboarding and training
• Helps improve adherence and access
• Extends field-team follow-up

Neurologists and MS centers are TG Therapeutics, Inc.’s core professional buyers for BRIUMVI, the anti-CD20 therapy for relapsing forms of multiple sclerosis. Their prescribing choices matter most in a U.S. market with about 1 million people living with MS and roughly 85% starting as relapsing MS, so clinic uptake can move revenue fast.

• Specialists treat relapsing MS
• They drive BRIUMVI uptake
• MS is a high-touch, referral market

Payers and health systems are key TG Therapeutics, Inc. buyers because they control formulary access, prior auth, and reimbursement for specialty drugs. In the U.S., specialty medicines are about 2% of prescriptions but roughly 50% of drug spend, so TG Therapeutics, Inc. must show clear clinical and economic value to win coverage.

• Control access and reimbursement
• Shape formulary placement decisions
• Need strong value evidence

General and administrative costs for TG Therapeutics, Inc. are the public-company overhead that pays for legal, finance, HR, audit, and compliance work, plus SEC reporting and board support. In 2025, these fixed costs sat alongside commercial scale-up and R&D, so they funded both development and BRIUMVI launch execution.

• Legal, finance, HR, compliance
• SEC reporting and audit costs
• Supports R&D and commercialization

TG Therapeutics, Inc. bears structural costs from partnering and licensing: milestone, royalty, and shared-cost payments can keep running as external programs advance, even after launch. In 2025, this model still mattered because the company’s growth leaned on in-licensed assets and collaboration terms, not just internal R&D.

• Milestones rise as programs progress
• Royalties stay tied to sales
• Shared costs hit cash flow

Upfront licensing fees can bring TG Therapeutics, Inc. cash before a drug ever reaches the market, and the Company has used in-licensing to build its pipeline, including ublituximab and umbralisib. That cash helps fund development and reduce near-term burn, which matters even more when BRIUMVI is still the main revenue driver.

• Immediate cash from in-licensing
• Supports pipeline funding
• Pairs with milestone payments

In 2025, TG Therapeutics, Inc. used collaboration and research reimbursements to recover part of shared R&D spend, helping trim operating burn while partner programs moved ahead. These receipts are usually smaller than product sales, but they matter because they fund work without adding full cost to TG Therapeutics, Inc.

• Offsets shared R&D cash burn
• Funds partner program progress
• Supports non-dilutive financing